KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Equity (2016 - 2025)

Historic Return on Equity for Halozyme Therapeutics (HALO) over the last 15 years, with Q4 2025 value amounting to 1.15%.

  • Halozyme Therapeutics' Return on Equity rose 600.0% to 1.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.15%, marking a year-over-year increase of 600.0%. This contributed to the annual value of 1.54% for FY2025, which is 4500.0% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' Return on Equity stood at 1.15%, which was up 600.0% from 1.42% recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Return on Equity peaked at 2.44% during Q2 2021, and registered a low of 1.06% during Q3 2024.
  • For the 5-year period, Halozyme Therapeutics' Return on Equity averaged around 1.56%, with its median value being 1.47% (2021).
  • Per our database at Business Quant, Halozyme Therapeutics' Return on Equity soared by 29300bps in 2021 and then tumbled by -12900bps in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Return on Equity stood at 1.68% in 2021, then fell by -10bps to 1.52% in 2022, then rose by 12bps to 1.69% in 2023, then tumbled by -36bps to 1.09% in 2024, then grew by 5bps to 1.15% in 2025.
  • Its Return on Equity stands at 1.15% for Q4 2025, versus 1.42% for Q3 2025 and 1.37% for Q2 2025.